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A b s t r A c t
Idiopathic intracranial hypertension (IIH) is a syndrome of increased intracranial 
pressure without evident cause. The exact pathogenesis of IIH remains elusive but it is 
also plausible that the syndrome represents the common final pathway of several dif-
ferent mechanisms. IIH has an estimated incidence of 1-3 per 100,000 and a predilec-
tion for obese women of childbearing age. Presentation involves symptomatology and 
semiology of elevated intracranial pressure, with headache being the most common 
symptom. Visual disturbances can be devastating, progressive, and may result in per-
manent visual loss. Moreover, pulsatile tinnitus is frequently encountered. However, 
asymptomatic presentations are also not uncommon, with patients diagnosed after 
routine ophthalmological examination illustrates papilledema. Diagnosis is based 
upon Friedman’s criteria. Absence of hydrocephalus or mass lesion and normal cer-
ebrospinal fluid composition need to be confirmed. Several treatment modalities have 
been suggested, varying from non-surgical (weight loss, drugs such as acetazolamide, 
serial lumbar punctures) to interventional and surgical (cerebrospinal fluid diversion 
procedures, optic nerve sheath fenestration, endovascular venous sinus stenting, or 
even bariatric surgery). There are very few randomized controlled trials that critically 
assess these therapies and, consequently, no consensus currently exists on the optimal 
management of IIH.
I N t r O D U c t I O N
Idiopathic intracranial hypertension (IIH) or pseudotumor cerebri, is a syndrome 
of unknown cause that results in elevated intracranial pressure (ICP). This condition 
occurs in the absence of hydrocephalus or mass lesion and patients have normal cer-
ebrospinal fluid (CSF) composition. Overall incidence is low (0.9/100,000), however, 
there is a predilection for obese women of childbearing age, in whom the incidence is 
nearly 20 times higher.1 Although the symptoms of IIH are not life-threatening, they 
can be incapacitating secondary to severe headaches, visual disturbance, and potential 
progression to blindness.
A syndrome which, in the absence of a mass lesion, was presented with brain tu-
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mour-like symptoms, named “meningitis serosa”, was initially 
reported by Quincke in the 1890s.2 Later on, Walter Dandy, 
one of the most distinguished figures of modern neurosurgery, 
introduced the surgical treatment of the disease by perform-
ing subtemporal decompressions in his patients. He described 
sporadic and rapid elevations of the craniectomy flaps within 
a period of minutes,3 hypothesizing a dynamic process (such 
as changes in the vasomotor vascular bed) underlying the syn-
drome’s pathophysiology.4 The nomenclature of the syndrome 
was updated in 1989, when Corbett and Thomson5 introduced 
the term “idiopathic intracranial hypertension”, to replace the 
previously used “pseudotumour cerebri” and “benign intrac-
ranial hypertension”, because those terms did not reflect the 
severity of the condition.
e P I D e M I O L O G y
Idiopathic intracranial hypertension has an annual inci-
dence of 0.9 per 100,000 in the general population, and 3.5 
per 100,000 in women aged 15-44 years old. However, in obese 
women of childbearing age (20-44 years old), who exceed the 
ideal weight by over 20%, the annual incidence is nearly 20 
times higher (19 per 100,000). The mean age at the time of 
diagnosis is 30 years.1 More than 90% of patients clinically 
diagnosed with IIH are women of childbearing age, and over 
90% are obese.6 One should be cautious when diagnosing 
IIH in the following categories: non-obese individuals, men, 
elderly, and very young children. The reason is that IIH’s 
incidence is low in such patients and alternate causes should 
be considered. In men diagnosed with IIH, black individuals 
have the greatest risk of visual loss.7 IIH affects children as 
well. However, the incidence does not differ between genders8 
and the association with obesity is less robust.9 Recent weight 
gain (within a year prior to diagnosis) has been correlated with 
IIH onset in both obese and non-obese patients.10
P A t H O G e N e s I s
“Idiopathic” derives from the Greek words “ίδιος” (idios), 
meaning “one’s own” and “πάθος” (pathos), meaning “suf-
fering”. It describes “a disease of its own kind” and is used to 
denote the unknown or obscure cause of a disease or condi-
tion. Consequently, as the term idiopathic indicates, the exact 
pathogenesis of IIH remains elusive. Any theory, in order to 
be plausible, should interpret the predilection of the syndrome 
for obese women of childbearing age, the normal size of the 
ventricular system, and the association of IIH with systemic 
diseases and particular medications (e.g. tetracyclines).11
Although several theories have been proposed to explain 
the pathophysiology of the syndrome, none has adequately 
done so. Consequently, IIH has been described as the “disease 
of theories” because no consensus exists as to its pathogenesis. 
However, it is plausible that the syndrome represents the com-
mon final pathway of several different mechanisms.
A .  c e r e b r O s P I N A L  f L U I D  ( c s f )  A b s O r P t I O N /
P r O D U c t I O N  A b N O r M A L I t I e s
The “impaired CSF absorption” theory seems to be the 
most popular. Decreased conductance to CSF outflow has 
been demonstrated through radioisotope cisternography.12 
The CSF is mainly absorbed through the arachnoid villi of 
the brain, although spinal arachnoid granulations and extrac-
ranial lymphatics have been suggested as possible alternative 
routes13,14 and decreased CSF absorption has been attributed 
to their disorder.15 Nevertheless, irrespective of the absorp-
tion process, if outflow resistance rises, then the intracranial 
pressure (ICP) must rise in order to allow CSF to be absorbed.
Overproduction of CSF has also been suggested as the 
etiology of the syndrome. However, the CSF production rate 
of IIH patients does not seem to be substantially different 
from that of asymptomatic control subjects.16 Moreover, an 
overproduction of CSF would probably result in hydrocepha-
lus, a condition which by definition is inconsistent with IIH.
b .  I N t r A c r A N I A L  v e N O U s  H y P e r t e N s I O N 
A N D  O b e s I t y
Intracranial venous hypertension has been suggested both 
as the initial step and the final pathway of IIH. The first argu-
ments about its etiologic nature in IIH were advanced follow-
ing direct venous manometry studies demonstrating elevated 
intracranial venous pressure in IIH patients.17 Elevated intra-
abdominal pressure in an obese patient can induce a cascade 
of elevated pleural, right atrial (preload), and central venous 
pressures and finally intracranial venous hypertension and 
IIH.18 Furthermore, hypercarbia encountered in sleep apnea, 
which is a known complication of obesity, can lead to intracra-
nial venous hypertension and IIH via cerebral vasodilation.19
c .  I N t r A c r A N I A L  v e N O U s  H y P e r t e N s I O N 
A N D  v e N O U s  s I N U s  s t e N O s I s
Venous outflow obstruction (venous sinus stenosis) has 
been implicated as the cause of intracranial venous hyperten-
sion and consequently decreased CSF absorption.20 With the 
utilization of auto-triggered elliptic-centric-ordered three-
dimensional gadolinium-enhanced magnetic resonance venog-
raphy (ATECO MRV), focal venous sinus stenoses, typically in 
the transverse or upper sigmoid sinus, have been encountered 
in 93% of IIH patients.21 and are attributed to hypertrophied 
pacchionian granulations in most cases.22
An alternative hypothesis suggests that venous sinus 
stenosis is the sequela of the syndrome, namely resulting 
from transverse sinus compression due to elevated ICP.23 In 
support, reduction in transverse sinus pressures after CSF 
withdrawal by lumbar puncture,24 and resolution of sinus ste-
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nosis after cerebrospinal fluid diversion,25 have been shown. 
Contrariwise, reports with persistent venous sinus stenoses 
after restoration of normal cerebrospinal fluid pressure have 
also been published.26
D .  v I t A M I N  A
Vitamin A, retinol binding protein (RBP) and retinol 
levels have been found to be increased in both cerebrospinal 
fluid and serum of IIH patients, implicating vitamin A in the 
pathogenesis of IIH.27,28 Theories suggest that either vitamin 
A enhances the transcription of genes associated with CSF 
production or absorption, thus causing intracranial hyperten-
sion29 or RBP functions as a signalling molecule affecting CSF 
production/drainage.30
e .  c e r e b r A L  e D e M A
Although cerebral edema constitutes one of the first sug-
gested theories of IIH pathogenesis with pathological findings 
evidenced in one study,31 ensuing studies have rejected this 
theory.32-34
f.  O t H e r  t H e O r I e s  A N D  A s s O c I A t e D 
c O N D I t I O N s
The influence of sex hormones in the pathogenesis of IIH 
has been postulated due to the predominance of the disease 
in women and a history of menstrual irregularities in many 
patients.35 Another hypothesis suggests that microthrombi (not 
evident on magnetic resonance imaging) may obstruct the CSF 
outflow in patients with thrombophilia and thus, induce intrac-
ranial hypertension leading to IIH.36 IIH has been repeatedly 
associated with various drugs (such as tetracyclines,37 vitamin 
A38) and systemic illnesses (such as lupus erythematosus,39 
uremia,40 hypothyroidism41).
c L I N I c A L  f e A t U r e s
By definition, presentation involves symptomatology and 
semiology of elevated intracranial pressure, with headache 
being the most common symptom. Visual disturbances can be 
devastating, progressive, and may result in permanent visual 
loss. Moreover, pulsatile tinnitus is frequently encountered. 
However, asymptomatic presentations are also not uncom-
mon42 with patients diagnosed after routine ophthalmological 
examination illustrating papilledema.
A .  H e A D A c H e
Idiopathic intracranial hypertension typically presents with 
headache, which is almost always present in the course of the 
disease.43,44 Headache features are that of a pulsatile in nature, 
worse in the morning, may awaken the patient, associated 
with photophobia, and often similar to migraine. Nausea and 
vomiting may accompany the headache.
b .  t r A N s I e N t  O b s c U r A t I O N s  O f  v I s I O N
Transient obscurations of vision (TOV) are short episodes 
-usually less than one minute- of monocular or binocular visual 
loss, constitute the most common visual symptom in IIH and 
may be attributed to momentary ischemia of the optic nerve 
head. Positional changes can, usually, trigger such episodes.45
c .  O c U L A r  M O t I L I t y  D I s O r D e r s
Diplopia is a common symptom in IIH patients and is, 
probably, attributed to sixth nerve palsy due to its constriction 
as it exits Dorello’s canal.46 However, any other cranial nerve 
palsy should prompt a search for an alternative diagnosis.
D .  t I N N I t U s
Pulsatile tinnitus in IIH has been attributed to turbulence 
of cerebrospinal fluid -through which vascular pulsations are 
being transmitted- through the venous sinus stenoses of IIH 
patients.21 Over half of IIH patients experience pulsatile tin-
nitus, which is unilateral in most instances.45
e .  PA P I L L e D e M A
Papilledema is the cardinal sign and the presumed etiol-
ogy of visual loss in IIH. However, pseudopapilledema (such 
as macular drusen or congenital disc abnormalities) is the 
main differential diagnosis that one should have in mind. 
Papilledema is classified using the “Frisen Scale”, after per-
forming fundoscopy and assessing the appearance of the optic 
disc.47 Thus, it can be categorized in 5 grades from normal optic 
disc (grade 0) to severe papilloedema (grade 5).
f.  v I s U A L  f I e L D s  A N D  v I s U A L  A c U I t y  L O s s
Visual loss may ensue as a consequence of neglected 
papilledema and is typically progressive. Formal perimetry, 
automated or Goldmann, is routinely utilized to evaluate 
visual fields. Nevertheless, automated perimetry generates 
more consistent and comparable values for future evaluations 
and thus, has a comparative advantage over Goldmann.48 The 
vast majority of IIH patients experience visual field defects. In 
particular, the most common by far is the enlargement of the 
blind spot while arcuate scotomas, nasal defects, and general 
field constrictions also occur.49 On the contrary, visual acuity 
assessed via corrected Snellen acuity scale, is typically normal 
except for fulminant and long term syndromes or in the con-
text of a detached retina. A possible explanation is that the 
papillomacular bundle remains unaffected until papilledema 
progresses to severe grades.49 Hence, visual acuity is a relatively 
poor method for evaluating visual deterioration in IIH. On the 
contrary, formal perimetry and fundoscopy constitute critical 
markers for the progression of the syndrome.
D I A G N O s t I c  c r I t e r I A
Diagnosis is based upon the “modified Dandy criteria”, 
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which were initially presented in 1985 and updated by Fried-
man (Friedman’s criteria) in 2002 (Table 1).50 All six criteria 
must be fulfilled. As such, IIH represents a diagnosis of 
exclusion.
Taking all of the above into consideration, a meticulous 
neurological examination, opthalmological assessment (fun-
doscopy, visual acuity and fields) together with pertinent 
brain imaging and lumbar puncture are necessary to make the 
diagnosis of IIH. In this context, the CSF opening pressure 
should be above 25 cm of water measured in the lateral decu-
bitus position.51 However, some argue that there is no explicit 
cutoff level, and values between 20 and 25 cm of water should 
be regarded as marginal.52
Magnetic resonance imaging (MRI) should arguably be 
a routine investigation to rule out hydrocephalus or mass 
lesion through the diagnostic process of IIH. However, due 
to the presumed involvement of venous sinus stenosis in the 
pathogenesis of the disease and the imperative exclusion of 
venous sinus thrombosis in order to diagnose IIH, magnetic 
resonance venography (MRV) might be a routine investiga-
tion in all patients with suspected IIH. MRI is normal in the 
vast majority of IIH patients. However, there are some MRI 
features, which are occasionally encountered. These are: small 
slit-like ventricles, empty sella due to presumed herniation 
of pituitary through the sellar diaphragm, enlarged perioptic 
subarachnoid spaces and flattening of the posterior sclera.53-56
As previously mentioned, IIH is a diagnosis of exclusion. 
Consequently, alternative diagnoses must be thoroughly con-
sidered. Particularly, absence of hydrocephalus, mass lesion, 
venous sinus thrombosis, hypertensive encephalopathy, pseu-
dopapillodema, and finally secondary intracranial hyperten-
sion due to drugs and systemic illnesses must be established.
M A N A G e M e N t
Due to the loose definition of IIH and the debatable cause 
of the syndrome, several treatment modalities have been sug-
gested over the years, varying from non-surgical to surgical. 
Current management options are:
 - Conservative: weight loss, drugs (acetazolamide, topira-
mate, furosemide, octreotide), repeated lumbar punctures.
 - Surgical and interventional: CSF diversion procedures 
(ventriculoperitoneal or lumboperitoneal shunting), optic 
nerve sheath fenestration (ONSF), venous sinus stenting, 
and bariatric surgery.
These treatments have two substantial objectives: a) pre-
vention of visual loss and preservation or even improvement 
of visual function b) alleviation of headache. There are no 
specific therapeutic recommendations for the treatment of 
IIH. Generally, IIH patients are treated along the following 
principles:
 - Νo intervention is needed if symptoms remain minor and 
visual function is unaffected. However, monitoring for pos-
sible visual deterioration, especially visual fields, is crucial.
 - Should presumed etiologic factors be present (such as 
tetracyclines or sleep apnea), they must be tackled.57
 - Medical treatment (using carbonic anhydrase inhibitors 
and loop diuretics) is the first step of the management and 
often suffices, halting the progression of IIH.58
 - Simultaneous weight reduction should be encouraged (if 
needed) along with symptomatic headache management.
 - In cases of inadequacy of medical treatment or progression 
to visual deterioration despite treatment, surgical interven-
tion should be considered.
A .  c O N s e r vA t I v e  M A N A G e M e N t
Weight loss
The benefits of weight loss in the management of IIH 
patients have been well known for over 30 years.59 Resolution 
of papilledema can be achieved even through a weight loss 
of approximately 6%, as suggested by retrospective studies.60 
Hence, the involvement of a dietician early in the course of 
the disease should be considered for patients with minimal 
symptoms and unaffected vision. Surgically induced weight 
loss will be discussed below.
Drugs
Acetazolamide, a carbonic anhydrase inhibitor, is the most 
popular medication for the management of IIH. Its effect 
seems to be multifactorial. Acetazolamide exerts its therapeu-
tic effect by decreasing the secretion of CSF via the reduction 
of sodium ion transport across the choroid plexus and the 
cardiac filling pressure (preload) via its diuretic effect.61 It is 
postulated that acetazolamide may also acts by altering the 
taste of foods62-64 and thus resulting in anorexia.
tAbLe 1. Friedman’s Criteria for the Diagnosis of Idi-
opathic Intracranial Hypertension (IIH)
I. Symptoms, if present, are only those of generalized 
intracranial hypertension.
II. Signs, if present, are only those of generalized intracranial 
hypertension or papilledema: Intact neurological exam with 
the exception of visual disturbances, sixth cranial nerve 
palsy, and papilledema
III. Elevated CSF opening pressure, ventricular or lumbar (in 
the lateral decubitus position)
IV. Normal CSF composition
V. Absence of hydrocephalus, mass lesion or venous sinus 
thrombosis on neuro-imaging
VI. No other explanation for the raised CSF pressure
CSF = cerebrospinal fluid
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Topiramate, due to its carbonic anhydrase inhibitory ef-
fect65 and furosemide, due to its diuretic effect66 have also 
been advocated as a means of reducing CSF pressure in the 
management of IIH. Corticosteroids, formerly utilized for 
treatment of IIH have been widely abandoned because their 
long-term serious side effects (such as weight gain and steroid 
withdrawal) outweigh the short-term beneficial effects.67
Serial high-volume lumbar punctures
Withdrawal of CSF by serial high-volume lumbar puncture 
has been advocated for the treatment of IIH.68 However, serial 
lumbar punctures are of limited long-term value because their 
therapeutic effect lasts only for 82 minutes,69 as this period of 
time is needed for CSF pressure to regain its former values.
b .  s U r G I c A L  M A N A G e M e N t
Fulminant presentations with ongoing visual deteriora-
tion and medically refractory cases are usually treated with 
surgery. The surgical indications, as suggested by Corbett and 
Thompson,5 are summarized in Table 2. Dandy advocated 
subtemporal decompressive surgery to manage IIH in the first 
place. Long-term satisfactory outcomes are published even in 
relatively recent series.4 Nonetheless, this surgical modality has 
been widely rejected and excluded from contemporary surgi-
cal management of IIH due to serious complications (such as 
seizures and subdural hematoma) and poor cosmetic result. 
The surgical procedures used in contemporary management 
are briefly described below.
CSF diversion procedures
Lumboperitoneal shunt (LPS) and ventriculoperitoneal 
shunt (VPS) constitute methods to divert the CSF from the 
lumbar subarachnoid space and the lateral ventricles of the 
brain, respectively, into the peritoneum. The techniques in-
volve introducing a silastic catherer between two lumbar verte-
brae into the subarachnoid space or through a burrhole in the 
lateral ventricles of the brain, for LPS and VPS respectively. 
The shunt is placed under the skin and follows the subcutane-
ous plane until it reaches the anterior abdominal wall just in 
front of the rectus abdominis, whereby through a breach in 
the peritoneum the catheter enters the intraperitoneal cavity.
Over the years, the CSF diversion apparatus has been 
enhanced through incorporation of an intermediate valve for 
adjustment of CSF flow. The valves used, can either control 
pressure differential between the two compartments (differ-
ential pressure valves) or regulate flow of CSF (flow-regulated 
valves), and allow for a relatively balanced release of CSF 
rather than rapid flow. An anti-siphon mechanism can be 
added to the CSF kit in order to counterbalance overdrain-
age/underdrainage due to postural changes (e.g. overdrainage 
when standing).
Traditionally, CSF diversion procedures are being per-
formed in patients with both headache and visual deteriora-
tion. The most probable explanation is that CSF diversion 
procedures achieve good results in both headache alleviation 
and visual improvement categories.70 Concerning VPS, it is 
usually difficult to cannulate the small-to-normal ventricles 
of the brain and the available technological adjuncts, such 
as neuronavigation, play an important role. Complications 
of these procedures like catheter obstruction are commonly 
encountered , and in many cases necessitate shunt revision.71
Optic nerve sheath fenestration
Optic nerve sheath fenestration (ONSF) was introduced 
by De Wecker in 1872.72 Firstly, the surgeon must gain ex-
posure of the optic nerve sheath, immediately posterior to 
the globe. The globe therefore must be rotated laterally or 
medially (depends on the technique). Subsequently, a couple 
of fenestrations in specific part of the optic nerve sheath are 
performed, sometimes augmented by excision of a window of 
dura between these fenestrations. The exact mechanism of 
action is not known. It is postulated that CSF flow through the 
dural window or sheaths forms a chronic fistula that prevents 
transmission of high CSF pressure to the optic-nerve head.73 
ONSF seems to be effective in improving visual function and 
pappiledema. However, it is less effective in alleviating head-
ache. Consequently, it is probably a better choice when the 
primary symptom is visual deterioration.
Venous sinus stenting
Focal stenosis of the transverse sinus (or upper sigmoid) 
has been demonstrated in many IIH patients. These stenoses 
have been implicated as either the causative or contributory 
cause of increased ICP, and thus focused treatment of the 
tAbLe 2. Indications for Surgical Intervention in Idiopathic 
Intracranial Hypertension (IIH)
1. If fail, intolerant to, or non-compliant with maximal 
medical therapy
2. New worsening visual field defect or enlargement of 
previously existing visual field defect
3. Reduced visual acuity not due to macular edema
4. Presence of severe visual loss (20/40 or worse) in one or 
both eyes at time of initial examination
5. Anticipated hypotension induced by treatment of high 
blood pressure or renal dialysis
6. Psychosocial reasons, such as patient’s inability to perform 
visual field studies, non-compliance with medications, an 
itinerant lifestyle
7. Headache unresponsive to standard headache medications
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stenotic sinus with a stent has emerged as a new potential 
treatment strategy. In particular, some argue that regardless 
of the role of sinus stenosis in IIH pathogenesis (causative 
or contributory), elevated prestenotic venous pressure must 
be restored because, either way it results in a vicious cycle of 
increasing ICP and worsening stenosis.49
Through a Seldinger technique, a catheter is advanced 
from the common femoral vein to the stenotic area of the 
transverse (or upper sigmoid) sinus. When the sinus stenosis 
has been reached, deployment of an attached-to-the-catheter 
expandable metal stent is being performed, thus enabling 
venous pressure to return to its normal values.
Transverse sinus stenosis and a specific pressure gradient 
across the stenosis need to be confirmed in order to proceed 
to venous sinus stenting. Considerable efficacy in visual, head-
ache, and pappiledema improvement has been demonstrated. 
However, much will depend on the durability of its effects, 
demonstrated in studies with longer follow-up, because a 
tendency for restenosis around intravascular stents at other 
sites has been widely recognized.74
Bariatric surgery
Most commonly, gastric bypass and in some cases lapa-
roscopic adjustable gastric banding (LAGB) have been per-
formed to treat IIH in obese patients. In Roux-En-Y gastric 
bypass procedure the stomach is divided to form a small 
proximal gastric pouch. The jejunum is typically divided below 
the ligament of Treitz, and the distal segment is thereafter 
elevated and surgically joined to the gastric pouch to create 
the alimentary (Roux) limb. Thus, food is bypassing the rest 
of the stomach, the duodenum and a part of jejunum.75
In laparoscopic adjustable gastric banding (LAGB) pro-
cedure, a band device with an inflatable balloon is placed 
around the gastric cardia, approximately 1 cm below the gas-
troesophageal junction. This inflatable balloon is connected 
by tube to a subcutaneous port attached to the rectus sheath. 
Injection of saline into the port will cause balloon inflation, 
which subsequently leads to narrowing of the stomach.76
Bariatric surgery efficacy in treating IIH has not been 
studied extensively. However, bariatric surgery offers a range 
of other beneficial effects in the IIH obese patients. Apart from 
achieving long-term weight loss, the majority of morbidly obese 
patients who undergo bariatric surgery experience at least 
improvement of diabetes, hypertension, hyperlipidemia, and 
obstructive sleep apnea.76 Of note, achieving significant weight 
loss in obese patients with IIH occurs gradually. Consequently, 
bariatric surgery is not appropriate for fulminant IIH cases or 
cases with progressive visual loss.77
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